Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 22, Issue 4, Pages 499-507Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2022.2026921
Keywords
Systemic lupus erythematosus; chimeric antigen receptors; cellular immunotherapy; B cell depletion; mouse models of autoimmune disease
Funding
- Lupus Research Alliance
- University of Tennessee, University of Tennessee Health Science Center
Ask authors/readers for more resources
Cell engineering has the potential to revolutionize the treatment of previously intractable diseases, such as autoimmune diseases, by purposefully controlling cell functions through the expression of chimeric antigen receptors.
Introduction Medicine stands at the threshold of a new era heralded by the vast potential of cell engineering. Like advances made possible by genetic engineering, current prospects for purposeful control of cell functions through cell engineering may bring breakthroughs in the treatment of previously intractable diseases. Areas covered Engineering of cytotoxic T cells for expression of chimeric antigen receptors (CARs) instructs them to attack and destroy malignant cells and thus provides an exciting new approach in oncology. A decade of practical experience and first-in-human trials encourage the search for new and broader uses of CAR technology, including in autoimmune diseases. Expert opinion Systemic lupus erythematosus is an example of a broader category of autoimmune diseases, for which cell engineering will provide a powerful new therapeutic approach. This article describes different types of CAR T cell strategies that will provide new treatment options for patients with autoimmune diseases and replace conventional therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available